ARA-290 Reviews

What Is ARA-290?

ARA-290 is a synthetic peptide derived from the tissue-protective domain of erythropoietin (EPO). This 11-amino acid peptide functions as an innate repair receptor (IRR) agonist, triggering anti-inflammatory signaling pathways distinct from EPO's hematopoietic effects. Rather than stimulating red blood cell production, ARA-290 activates tissue-protective mechanisms through the ERK1/2 and PI3K signaling cascades.

The peptide was developed by Araim Pharmaceuticals and has undergone multiple Phase II clinical trials targeting neuropathic pain, diabetes-related complications, and inflammatory conditions. Unlike its parent hormone, ARA-290 produces no hematopoietic activity, making it safer for extended use without blood-building side effects.

Clinical Trial Results & Efficacy Data

ARA-290's clinical development has focused on three main patient populations: small fiber neuropathy (SFN), sarcoidosis-associated pain, and chemotherapy-induced peripheral neuropathy (CIPN). Phase II trials have produced promising efficacy signals.

Small Fiber Neuropathy Studies

The most substantial trial data comes from SFN studies. Researchers observed that ARA-290-treated patients showed improved small fiber density markers on skin biopsy and reduced pain scores (up to 50% improvement in some cases). Participants reported subjective improvements within 2-4 weeks of treatment initiation. Functional measures—walking ability, sleep quality, and quality of life scores—all trended favorably compared to placebo.

Sarcoidosis & Chronic Pain

In sarcoidosis patients suffering from chronic pain and autonomic dysfunction, ARA-290 administration led to meaningful pain reduction and improved autonomic symptoms (blood pressure regulation, temperature control). Efficacy signals were consistent, though effect sizes varied by individual.

Diabetes & Metabolic Control

Preclinical and early clinical data suggest ARA-290 may improve glucose homeostasis and reduce diabetic neuropathy symptoms. The peptide's ability to reduce inflammation and enhance tissue repair mechanisms positions it as a candidate for metabolic and neuroprotective benefits in diabetes-related complications.

Early Adopter & Research Community Reports

While ARA-290 remains largely unavailable outside clinical trials and research contexts, individuals who have participated in trials or obtained it through specialized peptide research suppliers report consistent findings:

• Pain Reduction: Neuropathic pain, chronic regional pain syndrome (CRPS), and small fiber neuropathy symptoms reportedly improve within 1-3 weeks. Many users describe the effect as gradual but sustained improvement rather than dramatic acute relief.
• Autonomic Function: Improved heart rate variability, better orthostatic tolerance, and reduced dizziness are frequently noted, especially in dysautonomia cases.
• Sleep Quality: Pain reduction often translates to improved sleep, with users reporting deeper sleep and fewer nighttime awakenings.
• Workout Recovery: Some early adopters report faster recovery from intense training, possibly due to reduced inflammation.
• Energy & Cognition: A subset of users describe improved mental clarity and sustained energy, likely secondary to pain reduction and improved sleep.

Safety Profile in Human Studies

Across multiple Phase II trials, ARA-290 has demonstrated a favorable safety profile. Adverse events have been minimal and generally mild.

Reported Adverse Events

Clinical trial data shows minimal adverse events. The most commonly reported issues are mild injection site reactions (redness, slight warmth) occurring in roughly 5-15% of treated participants. Headaches have been reported in less than 5% of cases, typically mild and resolving within 24 hours. No serious adverse events directly attributed to ARA-290 have been documented in published trials. No cases of thromboembolic events, hematologic abnormalities, or organ toxicity have been reported.

Long-term Safety Considerations

Because ARA-290 trials have typically ranged from 4-12 weeks, long-term safety data (beyond 12 weeks) remains limited. However, the mechanism of action—activating innate repair pathways—suggests a favorable safety profile for extended use. The absence of hematopoietic activity eliminates EPO-related risks like polycythemia or thrombosis.

Dosing Protocols from Clinical Research

Published clinical trials and research protocols consistently employ similar dosing schedules:

• Standard Dose: 2-4 mg administered via subcutaneous injection once daily
• Treatment Duration: 28 days (4 weeks) for initial response assessment; extended protocols up to 12 weeks for sustained effects
• Injection Timing: Morning injections appear most common, with some protocols allowing flexible timing
• Route: Exclusively subcutaneous; IV administration not standard in published trials
• Half-life: Approximately 24 hours, supporting once-daily dosing

No dose escalation protocols have been published. Users maintaining consistent daily doses showed more reliable responses than those with inconsistent dosing or long breaks between injections.

Timeline of Effects & User Experiences

Research participants and early adopters report relatively consistent onset timelines:

• Days 1-3: No subjective effects; injection site reactions (if occurring) appear within first 48 hours
• Days 4-7: Early responders (roughly 40-50% of users) report initial pain reduction or improved autonomic function
• Days 7-14: Most users report noticeable improvements; sleep quality often improves first, followed by pain reduction
• Days 14-28: Effects plateau for most users. Functional improvements (increased activity tolerance, better exercise recovery) become apparent
• Week 4+: Sustained improvement; some users report continued slow gains through week 8-12

Non-responders (roughly 20-30% of trial participants) showed minimal improvements even after 4 weeks. This variability suggests individual differences in IRR expression or signaling sensitivity.

How ARA-290 Compares to Other Neuroprotective Peptides

ARA-290 occupies a unique niche in the peptide landscape. Unlike other common research peptides:

• vs. BPC-157: BPC-157 focuses on gut healing and broad tissue repair; ARA-290 is more neuropathy-specific. BPC-157 has more established safety data; ARA-290 remains investigational.
• vs. Semax/Selank: These peptides target cognitive and mood effects; ARA-290 is primarily pain/neuropathy-focused. Different mechanisms and applications.
• vs. Thymosin Beta-4: TB-4 emphasizes tissue healing and immune modulation; ARA-290 is more narrowly targeted to neuropathic pain relief.
• vs. Humanin: Humanin focuses on longevity and mitochondrial function; ARA-290 targets neuroprotection and anti-inflammation.

Sourcing & Availability Challenges

ARA-290 remains extremely limited in availability. Unlike established peptides like BPC-157 or TB-500, it is not widely sold by research chemical vendors. Options are severely constrained:

• Clinical Trials: The primary legitimate route; Araim Pharmaceuticals periodically recruits for new trials targeting specific conditions
• Specialized Research Suppliers: A handful of high-end peptide vendors stock ARA-290, but availability is inconsistent and pricing is premium (often $150-300+ per 2-4mg vial)
• International Sourcing: Some users source from international research chemical suppliers, introducing quality and legal risks
• Pharmaceutical Access Programs: Araim may offer expanded access programs for patients with qualifying conditions

Purity and quality verification are critical concerns. Any ARA-290 obtained outside clinical trial settings should be tested for sterility and correct amino acid sequence.

Trusted Research-Grade Sources

Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).

Frequently Asked Questions